Senior Vice President of Investor Relations
Good evening. Welcome to the Vertex First Quarter 2021 Financial Results Conference Call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Making prepared remarks on the call tonight, we have Dr. Reshma Kewalramani, Vertex s CEO and President; Stuart Arbuckle, Chief Commercial and Operations Officer and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides on our website as you listen to this call. This conference call is being recorded and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today s press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation those regarding Vertex s marketed CF medicines, our pipeline, expectations regarding the closing of the CRISPR transaction, which is subje
Senior Vice President of Investor Relations
[Technical Issues] relations for Vertex. Making prepared remarks on the call tonight, we have Dr. Reshma Kewalramani, Vertex s CEO and President; Stuart Arbuckle, Chief Commercial Officer; and Charlie Wagner, Chief Financial Officer; Dr. David Altshuler, Chief Scientific Officer; and Dr. Bastiano Sanna, Chief of Cell and Genetic Therapies will join the Q&A portion of the call following the prepared remarks. We recommend that you access the webcast slides on our website as you listen to this call. This conference call is being recorded and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today s press release and our filings with the Securities and Exchange Commission. These statements, including, without limitation, those regarding Vertex s marketed CF medicines, our pipeline and Vertex s future financial performance are b